Business Wire

EARNIX

23.5.2024 21:16:26 CEST | Business Wire | Press release

Share
Earnix Highlights the Potential of Synthetic Data in Specialty Insurance

Earnix, the leading global provider of AI-based SaaS solutions for financial services, today releases a high-level report highlighting the transformative potential of synthetic data to accelerate profitable growth and risk understanding in the context of the unique specialty London insurance market.

The white paper Reshaping London’s Specialty Market -The Impact of Technology and Data highlights the pivotal role that synthetic data - data that is produced, rather than gathered - will play in the future success of the market.

While synthetic data has been utilized in academia for decades, it's only recently gained traction in mainstream commercial applications. According to Gartner, synthetic data accounted for just 1% of data in 2021 but is projected to grow to 60% by 2024. Technological advancements like generational adversarial networks, transformers, and large language models have significantly increased the speed and volume of synthetic data created.

At the same time, the increasing demand for data in specialty insurance has prompted underwriters and brokers to begin harnessing synthetic data to supplement existing datasets, improving risk assessment efficiency. This is because synthetic data offers solutions to several key challenges in the London Market:

  1. Filling Data Gaps: Specialty insurers can harness synthetic data to access necessary data for product development and testing without compromising security or customer privacy. This has led to a surge in innovative ideas and technology deployment in insurance.
  2. Privacy and Security: Synthetic data maintains confidentiality while enabling critical analysis. In a world of widespread data availability, synthetic data techniques are essential to ensure customer data is not vulnerable to identity theft or fraud.
  3. Analytical Support: Synthetic data supports more accurate modeling, simulation, and testing, particularly in assessing extreme or rare events crucial for the specialty market, such as floods or hurricanes and fraud detection. Insurers can simulate these events to develop robust risk models without waiting for actual occurrences.
  4. Simulations, Stress Testing, and Data Expansion: Generating synthetic data improves the performance of predictive models, enhancing fraud detection and other analytical insights. It allows insurers to simulate and stress-test models in new situations, enabling them to introduce new products or expand into new segments or territories with limited existing data.

Earnix CEO Robin Gilthorpe said:

“The digital transformation of the London market’s complex specialty lines of business has only just begun. While it is a market-wide and fundamental shift in the way specialty insurers and reinsurers do business, it is not a one-size-fits-all solution. However, synthetic data coupled with AI, machine learning, and advanced analytics, holds promise for addressing various challenges in specialty insurance, including data gaps, privacy and security concerns, and fraud detection, among others.

Data plays a crucial role in revenue, profitability, and market share- particularly in this complex market where insight at a granular level can make a significant difference at a macro level. Specialty brokers and insurers know that in this rapidly evolving market, the ability to grow through change is paramount. Our white paper underscores the pivotal role of synthetic data in reshaping the London Market and outlines the next steps available to specialty insurers to harness the unparalleled opportunities for informed decision-making and enhanced operational efficiency.”

Download the report here.

For more information about Earnix, please visit www.earnix.com.

About Earnix

Earnix is the premier provider of mission-critical, cloud-based intelligent solutions across pricing, underwriting, rating, and product personalization. These fully integrated solutions provide ultra-fast ROI and are designed to transform how global insurers and banks are run by unlocking value across all facets of the business. Earnix has been innovating for insurers and banks since 2001, with customers in over 35 countries across six continents and offices in the Americas, Europe, Asia Pacific, and Israel. For more information please visit: earnix.com.

Contact Earnix via LinkedIn, X, and Facebook. Read the Earnix blog.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523060502/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SES and CANAL+ Strengthen Strategic Partnership Through 204027.10.2026 08:50:00 CET | Press release

SES and CANAL+, the global media and entertainment group, have extended their strategic partnership through 2040 with a multi-year agreement covering capacity across Europe, Africa and the Caribbean. Under the renewed agreement, CANAL+ will leverage SES’s satellite infrastructure across several orbital positions to deliver premium video and pay TV services to a global subscriber base that now exceeds 40 million viewers across 70 countries. "SES has been a trusted partner for more than 30 years, helping us deliver premium content to millions of viewers across Europe and Africa. This new agreement supports our long-term growth and provides the flexibility and reliability required as we continue to expand our international footprint and serve an increasingly diverse subscriber base," said Stéphane Baumier, Chief Technology Officer of CANAL+. "CANAL+ is one of SES's most valued and longest-standing customers. This agreement demonstrates the enduring importance of satellite in reliably deli

Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer27.10.2026 08:30:00 CET | Press release

Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 First EU approval of Enhertu in the curative-intent early breast cancer setting Third approval for Enhertu in the EU in four months Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for

Avanzanite Bioscience Expands UK Presence and Appoints Sarah O’Connell as Country Manager27.10.2026 08:00:00 CET | Press release

Avanzanite Bioscience B.V., a European pharmaceutical company focused on rare diseases, today announced the expansion of its United Kingdom (UK) presence and the appointment of Sarah O’Connell as UK Country Manager. The move strengthens Avanzanite’s long-term commitment to the UK and its ability to help eligible patients access innovative rare disease medicines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027035012/en/ Sarah O'Connell, Country Manager, UK, Avanzanite Bioscience “The UK is essential to our ambition of building Avanzanite into a European rare disease champion. We feel a deep and lasting connection to this market and there is no European reach without the UK,” said Adam Plich, co-founder and CEO, Avanzanite Bioscience. “At a time when parts of the life sciences sector are reassessing their investment and presence in the UK, we are choosing to commit and build for the long term. With Sarah’s extensive rare

LTM Secures Strategic Engagement with a Global Banking and Financial Services Firm27.10.2026 05:30:00 CET | Press release

LTM, the Business Creativity partner to the world's largest enterprises, has secured a strategic engagement with a large global banking and financial services firm, further strengthening its position as a trusted technology and transformation partner to leading financial institutions. This two-year engagement is already underway with an option to extend for an additional year and has a potential value of up to USD 100 million. The engagement reflects the continued expansion of LTM’s relationship with the client and its growing role in advancing strategic technology programmes and supporting supplier consolidation initiatives across the organization. Under the agreement, LTM will serve as a preferred partner driving the consolidation and delivery of strategic technology requirements across key wealth, personal banking, and global functions. The engagement will leverage LTM’s deep banking-domain expertise, engineering excellence, and global delivery capabilities to support the client’s t

DDN Selected to Modernize Research Data Infrastructure at UNSW Sydney26.10.2026 22:30:00 CET | Press release

DDN EXAScaler and Arcitecta Mediaflux will replace 11 legacy storage systems, simplifying access to research data while balancing performance and cost DDN, the global leader in AI and data intelligence solutions, today announced that UNSW Sydney has selected DDN to deliver a new research data storage environment as part of the university’s Research Data Experience (RDE) program. Working with Australian software company Arcitecta, DDN will combine its EXAScaler parallel file system with Arcitecta’s Mediaflux® data management platform to help researchers spend less time managing data and more time using it. Following an extensive 18-month evaluation, UNSW selected an integrated approach that will replace 11 legacy storage systems with a coordinated environment for high-performance storage and enterprise data management. The decision reflects a broader challenge facing research-intensive institutions: how to support rapidly expanding scientific datasets while simplifying infrastructure, i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye